LUCDHIGH SIGNALFINANCIAL10-K

LUCD shows strong revenue growth of 79% and dramatic improvement in gross profit margins, but net losses deepened significantly to $58M despite operational improvements.

The company demonstrates promising commercial traction with substantial revenue growth and a remarkable turnaround from negative to positive gross margins, indicating improving unit economics. However, the 27% increase in net losses suggests the company is still burning significant cash while scaling operations, raising questions about the path to profitability and cash runway sustainability.

Comparing 2026-03-25 vs 2025-03-24View on EDGAR →
FINANCIAL ANALYSIS

LUCD exhibited strong top-line growth with revenue increasing 79% to $4.3M and gross profit swinging dramatically from -$85K to +$377K, demonstrating improving operational efficiency and market traction. The balance sheet strengthened considerably with stockholders' equity doubling and total assets growing 32%, while accounts receivable surged over 1,300% reflecting the revenue acceleration. Despite these positive operational metrics, net losses deepened to $58M, indicating the company is investing heavily in growth while still burning substantial cash, creating a mixed picture of commercial progress alongside persistent profitability challenges.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
+1328.9%
$45K$643K

Receivables surged 1328.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Gross Profit
P&L
+543.5%
-$85K$377K

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

SG&A Expense
P&L
+200%
$7K$21K

SG&A up 200% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Stockholders Equity
Balance Sheet
+102.9%
$5.4M$10.9M

Equity base grew 102.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Interest Expense
P&L
-93.7%
$416K$26K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Revenue
P&L
+79%
$2.4M$4.3M

Strong top-line growth of 79% — accelerating demand or successful expansion into new markets.

Current Assets
Balance Sheet
+49%
$25.1M$37.5M

Current assets grew 49% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
-33.4%
$296K$197K

Capex reduced 33.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Assets
Balance Sheet
+31.7%
$30.7M$40.4M

Asset base grew 31.7% — expansion through organic growth, acquisitions, or capital deployment.

Net Income
P&L
-27.4%
-$45.5M-$58.0M

Net income declined 27.4% — review whether driven by operations, interest costs, or non-recurring items.

LANGUAGE CHANGES
NEW — 2026-03-25
PRIOR — 2025-03-24
ADDED
false --12-31 FY 2025 Our board administers its cybersecurity risk oversight function directly through our audit committee.
Our audit committee has primary responsibility for overseeing our risk assessment and risk management policies (including with respect to cybersecurity matters).
Our audit committee regularly discusses with management, counsel, and auditors the Company s major risk exposures.
This includes potential financial impact on the Company and the steps taken to monitor and control those risks.
Additionally, our board is informed regarding the risks facing the Company and coordinates with management and our cybersecurity team to ensure our board receives regular risk assessment updates from management.
+7 more — sign up free →
REMOVED
As of December 31, 2024 and March 20, 2025 there were 66,969,390 and 90,753,851 , respectively, shares of the registrant s Common Stock, par value $ 0.001 per share, issued and outstanding (with such number of shares inclusive of shares of common stock underlying unvested restricted stock awards granted under the Lucid Diagnostics Inc.
Securities and Exchange Commission within 120 days after the year ended December 31, 2024 .
Background and Overview Lucid Diagnostics is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease ( GERD ), also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma ( EAC ).
EsoGuard is a bisulfite-converted targeted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck.
It quantifies methylation at 31 sites on two genes, Vimentin (VIM) and Cyclin A1 (CCNA1).
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →